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Abstract
Background: Promoting the social value of global health research undertaken in resource poor settings has
become a key concern in global research ethics. The consideration for benefit sharing, which concerns the
elucidation of what if anything, is owed to participants, their communities and host nations that take part in such
research, and the obligations of researchers involved, is one of the main strategies used for promoting social value
of research. In the last decade however, there has been intense debate within academic bioethics literature
seeking to define the benefits, the beneficiaries, and the scope of obligations for providing these benefits.
Although this debate may be indicative of willingness at the international level to engage with the responsibilities
of researchers involved in global health research, it remains unclear which forms of benefits or beneficiaries should
be considered. International and local research ethics guidelines are reviewed here to delineate the guidance they
provide.
Methods: We reviewed documents selected from the international compilation of research ethics guidelines by
the Office for Human Research Protections under the US Department of Health and Human Services.
Results: Access to interventions being researched, the provision of unavailable health care, capacity building for
individuals and institutions, support to health care systems and access to medical and public health interventions
proven effective, are the commonly recommended forms of benefits. The beneficiaries are volunteers, disease or
illness affected communities and the population in general. Interestingly however, there is a divide between
“global opinion” and the views of particular countries within resource poor settings as made explicit by differences
in emphasis regarding the potential benefits and the beneficiaries.
Conclusion: Although in theory benefit sharing is widely accepted as one of the means for promoting the social
value of international collaborative health research, there is less agreement amongst major guidelines on the
specific responsibilities of researchers over what is ethical in promoting the social value of research. Lack of
consensus might have practical implications for efforts aimed at enhancing the social value of global health
research undertaken in resource poor settings. Further developments in global research ethics require more
reflection, paying attention to the practical realities of implementing the ethical principles in real world context.
Background
The social value of international health related research
at a minimum refers to efforts aimed at ensuring global
health research contributes to improvements in human
health, through for instance the generation and applica-
tion of generalisable knowledge [1], and has recently
become a key concern in global research ethics, espe-
cially when this research is undertaken in resource poor
settings. Various strategies have been devised to pro-
mote the social value of research including the call for
benefit sharing. This entails the elucidation of what if
anything, is owed to participants, their communities and
host nations that take part in such research. Other stra-
tegies include development of partnerships to identify
priorities for research [2] and community engagement
to enhance protection of research participants [3]. These
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research ethics guidelines that should provide direction
when considering benefit sharing. However, debates
continue in the academic bioethics literature relating to
defining benefits, beneficiaries, and the scope of obliga-
tions for providing benefits.
Debate over which benefits are ethically justifiable
show a division of opinion between those favouring
determination based on the type of research [4] and
those calling for a generic approach based on back-
ground issues of exploitation and oppression that pro-
duce ill health within resource poor settings [5-7].
Those in favour of the community as the appropriate
beneficiary, hold the view that providing benefits to only
those participating in research does not protect commu-
nities against exploitation, because it fails to engage with
the wider question of justice that connects community
health needs and the conditions of poverty that charac-
terise resource poor settings [7-10]. In contrast, those in
favour of benefiting individual participants maintain that
research does not and should not have a primary aim of
restoring inequalities or providing absent services, and
should therefore not be subject to the principles guiding
health care provision [11-13]. Debates relating to obliga-
tions for providing benefits mainly address the appropri-
ate limit or the scope of the benefits both during the
course of research (ancillary care responsibilities) and
after completion (post trial obligations). The debates are
mainly articulated by making reference to who should
be the beneficiary. Some people suggest that both spon-
sors and governments should be held responsible, espe-
cially for research studies aimed at wide deployment of
interventions addressing population health [14-16],
while others recommend development of collective
responsibility through partnerships, especially when the
anticipated benefits have huge financial implications
[17-20].
While these debates may be indicative of willingness
at the international level to engage with such ethical
issues in global health research it remains unclear which
position among those advanced in the literature should
be adopted, and how such positions should be justified
in ethical terms. The work reported here examines the
normative recommendations from various research
ethics guidelines regarding these responsibilities, as part
of a broader project examining the practical aspects of
promoting the social value of international collaborative
health related research undertaken in a resource poor
setting.
Methods
We reviewed documents selected from the international
compilation of research ethics guidelines by the Office
for Human Research Protections under the US
Department of Health and Human Services [21]. The
compilation contains 1,100 laws, regulations and guide-
lines governing human subjects’ research in 96 countries
worldwide. These laws and regulations are categorised
into those that provide general guidance to all human
subjects’ research and those that are specific to drugs,
genetic research, human biological materials, data pro-
tection/privacy and stem cell research.
The selection criteria were based on the relevance of
the guideline as sources of ethical guidance for research
related to health conducted in resource poor settings.
Relevance was determined on the basis of the jurisdic-
tion and the type of research covered. Research ethics
guidelines with a wider mandate in the sense that they
were expected to provide guidance to researchers in the
USA and Europe while conducting research in develop-
ing countries were included. The inclusion criteria were
limited to these regions since a high proportion of
health related research that is undertaken in Kenya, our
country of particular focus, involves collaboration with
researchers and institutions from Europe and the Amer-
icas [22]. Although it is acknowledged that there are
resource poor countries in other continents, the focus
within this study, were those in Africa.
Guidelines that provide general guidance for all types
of health related research, and those aimed at specific
types of clinical research
1 such as drug or vaccine trials
or general epidemiological studies including genetic
research were selected. This selection criterion was
based on the fact that much of the health related
research conducted in resource poor settings are drug
or vaccine trials and general epidemiological studies. In
terms of the geographical jurisdiction, guidelines/docu-
ments specific to the African region were identified
from the OHRP list. Due to the smaller number of
guidelines available online through the OHRP all the 7
out of 14 guidelines from African countries were
reviewed. The guidelines from Egypt, Botswana, The
Gambia and Malawi were not available online and
attempts to obtain them by writing to authors were not
successful. In addition guidelines from Brazil and India
were deliberately included in the review, due to the fact
that some of the initial Perinatal HIV Transmission
Trials [23,24] that triggered the fair benefits debates in
global health research were conducted in these coun-
tries. While the international compilation of guidelines
by the OHRP is not exhaustive, further literature search
to identify additional country specific guidelines was not
successful
2.
Based on theoretical literature on researcher’s respon-
sibilities in global health research a data abstraction
form was developed to provide a systematic framework
for recording information from the guidelines relating to
specific clauses that addressed responsibilities in terms
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mechanisms through which such decisions are made.
The information extracted from these documents were
organised into tables that were used in shedding light
o nt h en a t u r eo fr e c o m m e n d a t i o n sg i v e nb yd i f f e r e n t
research ethics guidelines.
Results
Description of the guidelines reviewed
The research ethics guidelines that were reviewed and a
brief contextual background on their jurisdiction are
presented in Additional file 1. The general guidelines
with a global jurisdiction that were reviewed include; i)
the Declaration of Helsinki by the World Medical Asso-
ciation (WMA), ii) the international guidelines for bio-
medical research involving human subjects by the
International Organisation for Medical Sciences
(CIOMS), iii) the guidelines for good clinical practice
(GCP) promulgated by the International Conference on
Harmonisation (ICH), iv) the Report on the Ethical and
Policy Issues relating to the conduct of Research Invol-
ving Human Participants by the US National Bioethics
Advisory Committee (NBAC), v) the statement on bene-
fit sharing by the Human Genome Organisation
(HUGO), vi) the report on the Ethical Aspects of Clini-
cal Research in Developing Countries by the European
Group on Ethics (EGE), vii) the Universal Declaration
on Bioethics and Human Rights (UDBHR) by United
Nations Educational Social and Cultural Organisation
(UNESCO), viii) the Report on the Ethics of Research
Related to health care in developing countries by the
Nuffield Council on Bioethics (NCOB) and the guidance
document on Ethical Considerations in biomedical HIV
prevention trial by the UNAIDS/WHO. Country-specific
guidelines that were included are those from Kenya,
Uganda, South Africa, Nigeria, Sudan, Zimbabwe, Ethio-
pia, India and Brazil.
The need to consider benefit sharing
Close to half of the guidelines reviewed have specific arti-
cles/clauses recommending consideration of the value of
research, or pointing to the need to engage with such a
consideration in general terms. Guidelines were exam-
ined for particular clauses that made specific mention of
the responsibilities of researchers in relation to the bene-
fits, the beneficiaries, obligations and the mechanisms
through which such decisions should be made. Table 1
shows the specific clauses identified within all the guide-
lines that address such responsibilities.
What forms of benefit sharing are recommended?
In most cases, the guidance relating to what benefits can
potentially be provided are articulated within a conti-
nuum of time when research is being undertaken.
Accordingly, research benefits are articulated as either
those that are concurrent to the conduct of research or
those that are expected after the research is complete.
Table 2 presents the forms of benefits that are recom-
mended by international and regional specific research
guidelines.
Table 3 presents examples of benefits which may be
considered while negotiating benefit sharing both during
and after research is complete. In the case of benefits
while research is on-going, access to interventions being
researched is recommended by most guidelines as a key
benefit by most of the guidelines. Other forms of bene-
fits include provision of unavailable health care, capacity
building for individuals and institutions, support to
Table 1 Exemplars of clauses supporting the need to consider research benefits
1
Guidelines Code/Report Relevant clause
Declaration of Helsinki
(2008)
Guideline 5 “In medical research on human subjects, considerations related to the wellbeing of the human subject
should take precedence over those of science and society”
Guideline 19 “Medical research is only justified if there is reasonable likelihood that the population in which it is carried
out stand to benefit”.
CIOMS (2002) Guidelines 5, 10, 11 and 12 require that information regarding benefits to participants, the community and how and
when these benefits shall be made available, be given during the consent process.
NBAC (2004) Part 4.2 states that “whenever possible/.../agreements should be negotiated/.../to make effective interventions or other
research benefits, available to the host country”,
ICH-GCP(1996) Part 4.3.2 states that “During and following a subject’s participation in a trial, the investigator/institution should ensure
that adequate medical care is provided to a subject for any adverse events, including clinically significant laboratory
values, related to the trial.../.
UDBHR 2005 Article 15 “the benefits resulting from any scientific research and its applications should be shared...”
Nigerian Ethics Code
(2006)
Section A, “research must have social and scientific value to either participants or the population that they represent,
the local community, host country or the world, in order to justify the use of finite resources and exposure to harm/
.../in collaborative studies...”,
Brazilian Resolution No.
196/96
Section III: part 3 M, “...research protocols should guarantee the individuals and communities where the research was
undertaken, a return on the benefits obtained in the research/.../when it is really beneficial to foster or encourage
changes in practices/behaviors in the interest of a community...”
Lairumbi et al. BMC Medical Ethics 2011, 12:22
http://www.biomedcentral.com/1472-6939/12/22
Page 3 of 8health care systems and access to medical and public
health interventions once they are proven effective.
The provision of unavailable health care services and
the support to local health care systems were not given
as key benefits especially among the international guide-
lines such as DoH and CIOMS. Where these are recom-
mended, provision of healthcare services encompasses
gaining regular contact with health care workers and
other measures that facilitate access to existing health
care services. In addition, the benefits that are expected
after research is complete mainly focus on the applica-
tion of generalisable knowledge from proven interven-
tions in their broadest sense. This can for instance be
seen in the tone of Article 33 of the DoH (2008)
3,A r t i -
cle 8 of CIOMS (2002) and UDBHR (2005) among
o t h e r s .I ts h o u l dh o w e v e rb en o t e dt h a ti nm o s tc a s e s ,
the benefits in question are rather aspirational in the
sense that they comprise the expected outcome of
research, including generalisable knowledge.
Who is the target beneficiary?
Three categories of beneficiaries are clearly evident from
the guidelines. The first category comprises research
participants; whether in the intervention or control
group. Research participants are mainly expected to ben-
efit from the intervention under investigation, and in
some cases, they are assumed to be the bona fide benefi-
ciaries of such interventions once they are proven to be
effective as exemplified by the tone of some guidelines
including the DoH, CIOMS, NBAC, NCOB and HUGO.
The second category of beneficiaries is the community
where research studies are undertaken or from which the
participants are drawn. Special groups such as People
Living with HIV and Aids (PLWHAs) or Men who have
Sex with Men (MSM) are also included in this category.
Guidelines that advocate for benefitting the host commu-
nity and other special groups include; CIOMS (Epide-
miology), HUGO, NBAC, and country specific guidelines
such as those by India, Nigeria, Uganda and Brazil. Inter-
estingly, guidelines by most developing countries focus
on benefits to the community as opposed to the indivi-
duals, perhaps, pointing to the preferred category of ben-
eficiaries in these settings. Such are likely to be in tension
with most prominent international guidelines like the
DoH, CIOMS, UNAIDS and to some extent the NCOB
do not feature in this category.
Table 2 Classification of forms of benefit sharing
Research Ethics Guidelines/Report/Code Form of Benefit sharing
Access to
Unproven
Interventions
Provide
H/care
Capacity
Building
Support to
health
system
Post
Trial
Access
Declaration of Helsinki (WMA)2008 ✓✓
Council for international Organisation for Medical Sciences(CIOMS) 2002 ✓✓ ✓
Council for international Organisation for Medical Sciences (Epidemiology) 2007 ✓✓
National Bioethics Advisory Commission Report 2001 ✓✓ ✓
Nuffield Council on Bioethics Report 2005 ✓✓
International Conference on Harmonisation –(GCP) 1996 ✓
Council of Europe 2003 ✓✓
HUGO Statement on Benefit Sharing 2000 ✓✓
UNESCO Declaration on Bioethics and Human Rights 2005 ✓✓ ✓ ✓ ✓
UNAIDS 2007 ✓✓
Guidelines by the |Kenya National Council for Science & Technology 2004 ✓✓
Ethiopian National Health Research Ethics Guideline(2005) ✓✓
National Guidelines for Ethical Conduct of Research Involving Human Subjects
by the Sudanese National Ministry of Health (Directorate General of Health
Planning and Research)
✓✓ ✓
Guidelines for researchers and Ethics Review Committees in Zimbabwe (Medical
Research Council of Zimbabwe) (2004)
✓✓
Ugandan Guidelines by the National Council for Science & Technology 2006 ✓✓
S. Africa MRC (2005) ✓
Nigeria National Code of Health Research(2006) ✓✓ ✓
Brazil 1996 ✓✓ ✓
India Council on Medical Research (ICMR) Code 2000 ✓✓ ✓
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referred to as the international community or society
more generally. Often, this group is considered in rela-
tion to aspirational benefits that may accrue from accu-
mulated generalisable knowledge. Such benefits include
improved health and lifestyles resulting from a robust
body of knowledge or availability of medicines to treat
diseases afflicting the society. Table 3 shows the party
(ies) expected to benefit by guideline.
Obligation for providing benefits and mechanisms for
making these decisions
There is little agreement amongst guidelines on how
responsibility for providing benefits should be appor-
tioned. Nonetheless, determination of responsibility
appears to be based on how potential benefits are
framed. For instance, when research benefits are seen as
a compensation for risk assumed by participating in
research, investigators and research sponsors are held
responsible. This compensatory approach to delineation
of responsibilities is mainly articulated by guidelines
such as the CIOMS, NCOB, and the UNAIDS. Other
guidelines that place responsibility on investigators and
sponsors include the Declaration of Helsinki, the Indian
Council for Medical Research, the Council of Europe
(CoE) and the Ugandan national guidelines for medical
research.
The scope of these obligations in terms of the benefi-
ciaries and the period is however limited to those parti-
cipating in research, and for the period before
interventions are proven to be effective or introduced
into the health care system. Some guidelines in this
category especially those by Uganda and India, however,
stretch this responsibility beyond benefits to individuals,
to include provision of benefits to the host community.
The Ugandan guideline for instance requires that inves-
tigators provide benefits while research is ongoing and
that research should assist in securing access of proven
interventions for the community. In both cases, the
responsibilities of the sponsor are confined to financial
support to aspects of the project and the provision of
indemnity in the event of research related injuries.
On the other hand, when potential benefits are con-
ceived from a social justice perspective including the
Table 3 Class of beneficiaries within research ethics guidelines
Category of Beneficiaries
Guidelines/Report/Code Volunteers/
individual
Participants
Trial/Disease
Community Res. Inst/
System
Larger
Community/Host
country
Declaration of Helsinki (2008) ✓
Council for international Organisation for Medical Sciences (2002) ✓
Council for international Organisation for Medical Sciences
(Epidemiology) (2009)
✓
National Bioethics Advisory Commission Report (2001) ✓✓
Council of Europe 2003 ✓✓
Nuffield Council on Bioethics (2005) ✓
HUGO Statement on Benefit Sharing (2000) ✓✓
UNESCO Declaration on Bioethics and Human Rights (2005) ✓✓ ✓
UNESCO Declaration on Human Genome and Human Rights (1997) ✓
UNAIDS (2007) ✓
Guidelines by the |Kenya National Council for Science & Technology
2004
✓
Ethiopian National Health Research Ethics Guideline(2005) ✓
Sudan ✓✓
Guidelines for researchers and Ethics Review Committees in Zimbabwe
by the Medical Research Council of Zimbabwe (2004)
✓✓
Ugandan Guidelines by the National Council for Science & Technology
2006
✓✓ ✓
S. Africa MRC (2005) ✓✓
Nigeria National Code of Health Research(2006) ✓✓
BRAZIL(1996) ✓✓
India Council on Medical Research (ICMR) Code 2000 ✓✓
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making them available is placed on all stakeholders
involved in the research enterprise including commu-
nities, researchers, the host government and sponsors.
Both the UNESCO declaration on human rights, the
NCOB and the Nigerian Research Ethics Committee for
instance place the responsibility to provide benefits on
all stakeholders involved in the research enterprise, by
emphasizing the importance of prior engagement among
stakeholders to identify and apportion responsibility.
Other guidelines that hold governments accountable for
providing proven interventions into the healthcare sys-
tem include the NCOB report, and the UNESCO
declaration on bioethics and human rights.
Prior consultation among parties to be involved in
research is the commonly recommended mechanism
through which the extent and scope of researcher’s
responsibilities are to be determined. Most guidelines
have specific clauses that point to the importance of
prior engagement. Guideline 10 of the CIOMS 2002 for
instance states that “before undertaking a study in a
population or community with limited resources, the
sponsor and the investigator must make every effort to
ensure that first, the research is responsive to the health
needs and priorities of the population or community in
which it is to be carried out”. Similarly, chapter 4.2 of
the report by the NBAC 2001
4 recommend that “when-
ever possible, preceding the start of research, agree-
ments should be negotiated by the relevant parties to
make the effective interventions or other research bene-
fits available to the host country after the study is com-
pleted”. Other guidelines including the HUGO
statement on benefit sharing, the NCOB report, and the
DoH similarly recommend prior consultation among
stakeholders to establish and agree on the benefits, who
to benefit and the nature and extent of stakeholder
responsibilities.
Discussion
Ethical guidance relating to the norms that should gov-
ern global health research especially when undertaken in
resource poor settings has come a long way. Their
development has been characterised by a shift from a
focus on protecting research participants from potential
for exploitation, to that wit ham o r eh o l i s t i cr e m i tf o r
securing community and host nation interests [2]. Most
notable of the developments are those recommending
community partnerships as avenues for delineating the
social value of global health research in local settings.
While these developments are welcome, danger signs
are beginning to show and further progress in this area
will need to engage with the root cause of the signs. For
instance, while it is acknowledged that normative guide-
lines are meant to provide broad directives as opposed
to prescription of specific actions, we have shown that
there are disparities among guidelines regarding the
responsibilities of researchers to participants and the
community. With regard to the forms of benefits, some
guidelines do not for instance consider access to
research interventions as benefits, while in others these
are clearly seen as such. Additionally, only a handful of
guidelines recommend support to the health care system
as a potential benefit while others clearly regard this as
a key benefit. We are not suggesting that access to
unproven research interventions or support to health
care are necessary ingredients of a set of benefits from
research but rather raisin gt h ei s s u et h a td i f f e r i n g
recommendations have obvious potential to result in dif-
fering practical interpretations of the ethical conduct of
global health research.
Furthermore it is not clear how stakeholders can make
decisions relating to the benefits, the party to benefit
and the nature and extent of responsibilities for making
these benefits available that would be ethically defensible
after consulting all the research ethics guidelines identi-
fied. The tension arising from this lack of clarity is likely
to be exacerbated by the fact that different stakeholders,
if they have a choice, are likely to make decisions on
their responsibilities on basis of the guidelines that most
suit their preferences. This may be particularly likely
given the potential financial implications for stake-
holders funding research.
Interestingly, differences in emphasis regarding poten-
tial benefits and the beneficiaries are clearly evident
between guidelines which perhaps represent the divide
between “global opinion” and the views of particular
countries within resource poor settings. Most interna-
tional research ethics guidelines for instance recommend
research participants as the key beneficiary, while those
from resource poor settings demonstrate considerable
interest in benefitting not only the participants, but also
the trial community and even the host country (as
shown in Table 3).
Lastly, there is some consensus among guidelines that
the nature of the researcher’s responsibilities be deter-
mined through prior engagement with local commu-
nities, the implication being that a practical mechanism
exists to achieve this end. However, the likelihood of
this process reaching consensus is questionable in the
face of disagreement over benefits, the beneficiaries and
by extension, the scope of obligations for providing
these benefits. Indeed the appropriateness of prior
engagement through such strategies as community con-
sultation remain unclear judging from the debates relat-
ing to the difficulties of identifying the community to
consult or even who the representatives are in cases
where a ‘community’ is evident [25-28]. More practical
challenges relate to the time appropriate for undertaking
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munity input to determine the nature of benefits is
often not undertaken as consultation usually takes place
only after the research protocol has been written and
approved by the Institutional Review Boards (IRBs)
[25,30]. The challenges faced by stakeholders who wish
to undertake prior engagement should also be under-
stood in the context of poorly functioning ethical gov-
ernance systems often staffed with personnel ill-qualified
to offer ethical guidance and contemplation [30-36].
Given these challenges and the different emphases in
guidelines it therefore seems quite possible that different
actors tackling the same research question but in differ-
ent contexts might come up with very different conclu-
sions with regard to benefits, beneficiaries, and
obligations and thus very different perspectives on the
social value of their research. Future developments
within the ethics of global health research undertaken in
resource poor settings will most likely benefit from
further reflection on the broader ethical principles and
from consideration of the practical realities of imple-
menting these principles in real world context.
These findings should however be interpreted with
some caution as documents provide only one window
on the wider ethics discourse. It may not be possible to
generalize to all low-income settings as most of the
country specific guidelines reviewed were, by design,
drawn from African countries with difficulties retrieving
documents from a number of settings with the specific
addition of the Indian and Brazilian guidelines. Were it
to be possible, inclusion of more guidelines from the
rest of the African settings would have provided a dee-
per context to our findings. In addition, we acknowledge
that development of these guidelines was unlikely to be
in isolation and there is potential for influence across
countries and documents. No attempt was made to
trace these interactions chronologically; something that
may have helped put observed differences in context.
Conclusion
Review of academic and policy literature in bioethics
and the analysis of recommendations by research ethics
guidelines point to a consensus that global health
research undertaken in resource poor settings should be
socially relevant and provide appropriate benefits if indi-
vidual participants and populations are to be treated
ethically. In theory consideration for benefit sharing is
widely accepted as one of the means for promoting the
social value of international collaborative health research
although, as evidenced by intense debates within aca-
demic and policy literature in bioethics, there is not
necessarily agreement on how benefit sharing should be
approached. There is less consensus amongst major
guidelines on the specific responsibilities of researchers
over what is ethical in promoting the social value of
research. Lack of consensus might have practical impli-
cations for efforts aimed at enhancing the social value of
global health research undertaken in resource poor
settings.
Appendix 1: Footnotes
1 The National Institutes of Health adopts a three part
definition of clinical research which includes; 1. Patient-
oriented research. Research conducted with human sub-
jects (or on material of human origin such as tissues,
specimens, and cognitive phenomena) for which an
investigator (or colleague) directly interacts with human
subjects. Excluded from this definition are in vitro stu-
dies that utilize human tissues that cannot be linked to
a living individual. Patient-oriented research includes:
(a) mechanisms of human disease, (b) therapeutic inter-
ventions, (c) clinical trials, or (d) development of new
technologies; 2. Epidemiologic and behavioral studies, 3.
Outcomes research and health services research.
2 Other sources including the compilation by the
WHO were also visited including; http://www.who.int/
ethics/research/en/index.html, databases on research
ethics guidelines such as the one by Indiana University
center for bioethics http://www.bioethics.iu.edu/body.
cfm?id=87 and the global ethics observatory by
UNESCO http://www.unesco.org/new/en/social-and-
human-sciences/themes/global-ethics-observatory/
access-geobs/
3 As adopted during the 59th WMA General Assem-
bly, Seoul, October 2008
4 Available at http://bioethics.georgetown.edu/nbac/;
Accessed 09.11.2011
Additional material
Additional file 1: Research ethics guidelines and policy documents
reviewed. Research ethics guidelines and policy documents on global
health research. Brief summaries on the key research ethics guidelines
and policy documents that have been developed to provide direction
on matters relating to the protection of research participants and their
communities when they participate in global health research.
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